Ocugen Rallies on Broker Upgrades

Ocugen is seeing renewed interest after buy initiations from Oppenheimer and Canaccord, which see significant upside in its pipeline of ophthalmic gene therapies. These recommendations, together with high price targets, are supporting the stock and reviving hopes around the next clinical and regulatory milestones for OCU400 and the company’s other assets. At the same time, the story remains highly speculative: cash burn is rising, dilution remains a risk, and the auditor has issued a going-concern warning. The stock could therefore stay very volatile, with a short-term boost driven by brokers, but an elevated risk profile until late-stage data and funding are secured.